These results were presented at a conference in 2019. In this trial, the researchers looked at the drugs bevacizumab, gemcitabine and pegylated liposomal doxorubicin. Bevacizumab (Avastin) is a ...

According to global pharmaceutical market research firm IQVIA on Wednesday, Vegzelma, also known for its active ingredient bevacizumab, held 29% market share in Europe at the end of the third quarter ...

Patients with stage II or III colon adenocarcinoma were stratified by number of positive lymph nodes and then randomly assigned to receive either modified FOLFOX6 for 6 months or modified FOLFOX6 for ...

The study is evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. The trial is continuing and ...

Patients treated with pembrolizumab plus paclitaxel with or without bevacizumab had a statistically significant and clinically meaningful improvement in PFS, regardless of PD-L1 status.

Pembrolizumab (Keytruda) plus paclitaxel with or without bevacizumab (Avastin) led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients ...

Objective: Alkylating agents and bevacizumab are both first-line chemotherapeutic options for the treatment of glioblastoma; however, their mechanisms of action differ substantially. This study aimed ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus chemotherapy in patients with PD-L1–positive, platinum-resistant recurrent ovarian ...

Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Bevacizumab - Biosimilar Insight, 2025" has been added to ResearchAndMarkets.com's offering. Bevacizumab - Biosimilar Insight, 2025 offers an in-depth ...

Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real ...

MONDAY, May 12, 2025 (HealthDay News) — The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic ...